Detalhe da pesquisa
1.
Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.
Haematologica
; 104(12): 2465-2481, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30948493
2.
Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL.
Blood
; 122(15): 2641-53, 2013 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23974204
3.
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.
Leukemia
; 37(8): 1671-1685, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37386079
4.
Phorbol ester-induced PKCepsilon down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation.
Blood
; 113(13): 3080-7, 2009 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-18988868
5.
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
Blood
; 112(6): 2450-62, 2008 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18583568
6.
Emerging MEK inhibitors.
Expert Opin Emerg Drugs
; 15(2): 203-23, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20151845
7.
Emerging Raf inhibitors.
Expert Opin Emerg Drugs
; 14(4): 633-48, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19715444
8.
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
Curr Opin Investig Drugs
; 9(6): 614-30, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18516761
9.
Early proinflammatory activation of renal tubular cells by normal and pathologic IgG.
Nephron Exp Nephrol
; 100(2): e77-84, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15775721
10.
MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors.
Hematol J
; 3(2): 105-13, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12032872
11.
Targeting the cancer initiating cell: the ultimate target for cancer therapy.
Curr Pharm Des
; 18(13): 1784-95, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22394167
12.
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.
Aging (Albany NY)
; 3(3): 192-222, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21422497
13.
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
Oncotarget
; 2(3): 135-64, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21411864
14.
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role?
Lung Cancer
; 50(3): 419-20, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16125820
15.
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting.
Clin Cancer Res
; 15(21): 6495-502, 2009 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19861456
16.
Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review).
Mol Med Rep
; 1(2): 139-60, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-21479390
17.
The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis.
Blood
; 110(13): 4464-75, 2007 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17848618
18.
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis.
Blood
; 107(11): 4549-53, 2006 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16467208
19.
Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4.
Ann Hematol
; 85(10): 681-7, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16733740
20.
Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells.
Blood
; 104(2): 519-25, 2004 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15031205